2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Profiling, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Study Population, Human, Adult
PAPER

2101 Altered transcriptional state in naïve T cells marks senescence-associated loss of CART cell fitness in chronic lymphocytic leukemia

Charles Joseph Kuhlmann, PhD, Emmanuel Contreras Guzman2, Brooke L Kimball3, Elizabeth Louise Siegler, PhD4, Long K Mai, BS5, Truc Ngoc Huynh, MS6, Grace Elizabeth DeFranco, BS7, Jennifer Meyer Feigin, BS8, Sophia Yael Goldberg9, Dominic Ambrosio Skeele10, Ateka Saleh11, Claudia Manriquez-Roman, PhD12, Omar Gutierrez-Ruiz, PhD13, Ismail Can, PhD14, Yoh Yamaguchi, MD15, Mehrdad Hefazi Torghabeh, MD16, R. Leo Sakemura, MD,PhD17, Lindsey Elizabeth Roeker, MD18, Paul J. Hampel, MD19, Zhiquan Wang, Ph.D20, Esteban Braggio, PhD21, Moritz Binder, MD, MPH22, Sameer A. Parikh, MBBS23, Neil E Kay, M.D.24, Saad Kenderian, M.B., Ch.B.25
1 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
2 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States
3 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
4 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
5 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
6 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
7 Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
8 Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
9 Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
10 Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
11 Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
12 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
13 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
14 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
15 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
16 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
17 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States
18 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States
19 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States
20 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States
21 Department of Cancer Biology, Mayo Clinic, Rochester, Minnesota, United States
22 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States
23 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States
24 Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States
25 Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States, Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States, Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, T Cell Engineering Laboratory, Mayo Clinic, Rochester, Minnesota, United States

CD19-directed Chimeric antigen receptor T (CART) cell therapy has emerged as a potentially curative option for Chronic Lymphocytic Leukemia (CLL), but the complete response rate in CLL is lower compared to other hematologic cancers. While CLL is characterized by an immunosuppressive state and baseline T cell defects, it remains unclear how CLL derived CART cells are biased toward these dysfunctional fates. Here we hypothesize that CLL leukemic cells lead to skewing of CART cell starting materials to promote CART cell dysfunction, limiting CART cell efficacy.

We tested this hypothesis using two cohorts of CLL patients. First, we assembled a cohort of 28 patients with CLL refractory to Bruton’s Tyrosine Kinase (BTK) inhibitors. Peripherial blood samples were taken on-treatment at the time of progression.  We interrogated the genome, transcriptome, and epigenome of leukemic CLL cells. We then characterized blood-derived T cells through flow cytometry, scRNA-seq, and scTCR-seq, and generated CD19 CART cells (FMC63-41BB-CD3ζ) from each patient and profiled them by flow cytometry and in vitro proliferation assays. Samples were stratified into strong and weak CART performance groups and compared to assess differences in T cell and tumor phenotypes. To validate these findings, we used a second cohort of samples from 18 patients with CLL treated with liso-cel with available clinical outcome data, with samples taken before the start of liso-cel treatment (baseline samples).

CART19 cells derived from CLL patients showed lower expansion during manufacturing (0.94 vs 2.6 doublings, p=0.0002), with significantly more PD1+/TIM3+ cells (39 vs 16%, p<0.0001), significantly higher mean fluorescent intensity (MFI) of CD57 (MFI 1817 vs 487, p=<0.0001), and lower MFI of CD27 (MFI 13,140 vs 30,180, p=0.036), suggesting that CLL derived CART cells suffer from dysfunctional states. In an in vitro proliferation assay, CLL patient derived CART19 cells had lower antigen-induced proliferation (4.8 vs 7.9-fold expansion, p=0.0158). We stratified our samples into ‘strong’ and ‘weak’ CART cell groups using the range of expansion in healthy controls as a cutoff (9 strong samples vs 19 weak samples, average 8.45 vs 2.78-fold expansion). CART cells in the strong group had higher central memory phenotypes (81% vs 55%, p<0.0001), higher CD27 expression (MFI 19,407 vs 10,318, p=0.0069), and lower expression of CD57 (MFI 1020 vs 2061, p=0.023 in CD8+) and PD1 (MFI 754 vs 2,506, p=0.0149); similar trends were noted for CD27 expression and central memory status in the validation cohort. These results suggest that terminal differentiation limits the performance of CART cells derived from CLL patients.

We performed paired scRNA-seq/scTCR-seq in the blood-derived T cells of the CLL patients and observed that patients with strong CART cell performance had increases in naïve CD4+ and CD8+ T cell populations, increased TCR diversity, and decreases in activated CD8+ T cell populations. Compared to healthy donors, CLL disease status drove higher transcription of the p15 (CDKN2B, log2 fold change (log2FC) 5.7, padj=0.0145) and p16 (CDKN2A, log2FC 3.25, padj=0.0058) genes in the naïve CD4+ T cell population. Interestingly, patients with strong CART cell performance had significantly lower CDKN2B (log2FC -3.4, padj=0.005) and CDKN2A (log2FC -2.24, padj= 0.011) transcription in starting naïve CD4+ T cells, greater TCR diversity in activated CD4+ T cells, and had lower frequencies of mature CD4+/CD57+/KLRG1+ T cells by flow cytometry (7.1% vs 18%, p=0.038), suggesting that CDKN2B and CDKN2A transcripts in the naïve fraction are associated with the accumulation of senescence and poor CART cell performance. Leveraging paired bulk RNA-seq of CLL leukemic cells, we analyzed gene expression changes associated with CART cell performance in our assay, revealing upregulation of genes associated with weak CART cell performance including BAMBI (log2FC 2.66, padj= 0.007), ZDHHC15 (log2FC 2.34, padj=0.009), and EGR1 (log2FC 3.03, padj=0.00018). In conclusion, these results suggest that changes in CLL leukemic cells are associated with skewed naïve CD4+ T cells and dysfunction of the final CART cell product. Future work will seek to characterize key interactions that may serve as targets for improving T cell fitness for CART cell therapy in CLL.

Charles Joseph Kuhlmann, PhD: No relevant conflicts of interest to declare.